bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.06.10.731356

An effector protein that protects a fungal pathogen from the plant microbiota during host colonisation

Abstract

Zymoseptoria tritici is the causal agent of Septoria tritici blotch, one of the most economically important wheat diseases worldwide. One of the few cloned wheat resistance genes against Z. tritici, Stb6, recognizes the secreted fungal effector AvrStb6. Although AvrStb6 has been extensively studied as an avirulence determinant, its biological function during host colonization remains unknown. Based on the amphipathic nature of the predicted structure of AvrStb6, we hypothesized the effector to function as a membrane-active antimicrobial protein. However, in vitro growth inhibition assays demonstrated that AvrStb6 does not directly inhibit the growth of wheat-associated bacteria across multiple bacterial genera and experimental conditions. Instead, microbiome analyses of wheat apoplastic fluid revealed shifts in bacterial abundance associated with the presence or absence of AvrStb6 in a susceptible cultivar (without Stb6-induced resistance). This prompted us to further explore other putative microbiome-related functions of AvrStb6. In vitro confrontation assays further showed that deletion of AvrStb6 increased the sensitivity of Z. tritici to antagonistic wheat-associated bacteria, particularly Pseudomonas and Pantoea spp. This phenotype was conserved across independent fungal genetic backgrounds and across virulent and avirulent AvrStb6 variants. Fluorescence-based co-culture assays additionally showed reduced fungal growth and increased bacterial proliferation in the absence of AvrStb6 during interactions with Pseudomonas spp., but not with the control bacterium Escherichia coli. Finally, biochemical assays demonstrated that AvrStb6 associates with the Z. tritici cell wall in vitro, whereas other secreted fungal effectors do not. Collectively, our findings identify a previously uncharacterized role of AvrStb6 in protecting Z. tritici from antagonistic wheat-associated bacteria by associating with the fungal cell wall. More broadly, this work highlights that fungal effectors may contribute to microbial competition and ecological adaptation beyond their established roles in host immune recognition. Author summaryPlant pathogens secrete proteins that help them colonize their hosts. Some of these proteins are recognized by plant immune receptors and trigger disease resistance, but their original biological functions often remain unclear. We investigated the role of AvrStb6, a protein produced by the wheat pathogen that causes Septoria tritici blotch. AvrStb6 is best known because it is recognized by a wheat resistance gene, yet its contribution to fungal growth and survival has remained unknown. We initially tested whether AvrStb6 directly inhibits bacteria that live on wheat leaves, but found no evidence that it acts as an antimicrobial protein. Instead, we discovered that AvrStb6 influences interactions between the pathogen and wheat-associated bacteria. Fungal strains lacking AvrStb6 were more sensitive to several bacterial species that naturally occur in wheat, particularly members of the genera Pseudomonas and Pantoea. We also found that AvrStb6 can associate with the fungal cell wall, suggesting that it helps protect the pathogen during encounters with antagonistic bacteria. Our findings reveal an unexpected role for a fungal effector in microbial competition and show that pathogen proteins traditionally studied in the context of plant immunity can also influence interactions with other microbes. This work highlights the importance of considering the broader microbial community when studying plant-pathogen systems.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Florez, L., Francisco, C., Berndt, H., Leippe, M., Cassidy, L., Tholey, A., Sanchez Vallet, A., Stukenbrock, E., Flores-Nunez, V.. 2026-06-11. An effector protein that protects a fungal pathogen from the plant microbiota during host colonisation. https://doi.org/10.64898/2026.06.10.731356

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Negative association between nodular stromal fibrosis and large lipid droplets in human choroid plexus epithelial cells

Fibrosis is an age-related change within the human choroid plexus that is likely to affect its function negatively. We systematically analyzed nodular stromal fibrosis present in postmortem tissue from a large repository encompassing the human lifespan. Following manual annotation of sampled images from 81 specimens of choroid plexus from the atrium of the lateral ventricle, a deep learning model was trained to assess stages of fibrosis (dense, hyalinized, and mineralized) occurring in papillae across whole slide images of hematoxylin and eosin-stained sections from 204 cases. The percentage of affected papillae and the relative area of fibrosis at all three stages of severity increased with age. Affected papillae were significantly clustered across the choroid plexus, with areas of high and low fibrotic density. Choroid plexus epithelial cells (CPECs) associated with fibrotic papillae were less likely to contain large lipid droplets than were non-fibrotic papillae, as assessed by another deep learning model. Across papillae within a case, the area of each stage of fibrosis was negatively correlated with the prevalence of CPECs containing large lipid droplets. Finally, individuals displaying more nodular fibrosis had significantly fewer CPECs containing large lipid droplets. Thus, age-related nodular stromal fibrosis may negatively impact lipid storage and homeostasis for the choroid plexus and brain.

pathology↗

SilencioM: silencing connected interfering oligonucleotides against MAPT as a potential disease modifying therapeutic for tauopathies

Tauopathies are a diverse group of neurodegenerative diseases whose pathogenesis involves brain accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). More than twenty tauopathies have been identified thus far that collectively impact millions of people worldwide, of which the most common is Alzheimer's disease (AD). Despite substantial efforts to develop drugs for tauopathies, no effective treatments currently exist, highlighting the urgent need for therapeutics to combat these prevalent and ruinous neurodegenerative diseases. Strategies that target tau are likely to have the greatest impact since tau is the proximal cause of their pathogenesis. Small interfering RNAs (siRNAs) have emerged as a powerful class of precision therapeutics that silence disease-causing genes through RNA interference with favorable safety profiles. Delivery challenges are rapidly being addressed, and siRNA-based approaches are poised to transform the therapeutic landscape of neurological diseases. In this study, we describe SilencioM (Silencing connected interfering oligonucleotides against MAPT) and show its efficacy in markedly reducing tau pathology after a single intracerebroventricular injection in PS19 mice, a mouse model of severe tauopathy. SilencioM targets human, primate, rat and mouse ortholog genes; thus, the same compound can proceed from efficacy studies to Investigational New Drug Application (IND)-enabling studies. SilencioM is simple to manufacture and is administered without encapsulation in lipid nanoparticles and without requirements for lipophilic conjugation, making it a promising candidate for further development as a novel therapeutic for tauopathies, including AD.

pathology↗

SilencioMA: A single compound that targets both MAPT and APP as a potential disease modifying therapeutic for Alzheimer's Disease

Alzheimer's Disease (AD) is the most common age-related neurodegenerative disease and the leading cause of dementia worldwide. AD pathogenesis involves aggregation of amyloid-beta (A{beta}), produced from amyloidogenic proteolytic processing of Amyloid Precursor Protein (APP), and accumulation of misfolded, pathological tau (Microtubule Associated Protein Tau, MAPT). Current efforts focus on developing disease modifying therapeutics (DMTs) against single targets: A{beta} or tau. However, DMTs that concurrently target both tau and A{beta} are likely to have the greatest impact since they target both culprits of AD pathogenesis. Here we describe the development of SilencioMA, a single compound that targets both MAPT and APP messenger RNAs (mRNAs) based on silencing connected interfering oligonucleotides against MAPT and APP. Cerebrospinal fluid (CSF) administration of SilencioMA reduces A{beta} and tau and pathology after a single intracerebroventricular injection in 5XFAD/PS19 mice, an animal model of severe amyloidosis and tauopathy. SilencioMA does not rely on lipid nanoparticles or lipophilic conjugates for CSF administration. At the same time its modular design permits conjugation of ligands that facilitate transcytosis through the blood brain barrier, allowing systemic administration. Our findings provide proof-of-concept for a strategy that targets the dual A{beta} and tau pathologies of AD, and establishes a compelling foundation for further development of SilencioMA as a next-generation DMT for AD.

pathology↗